Experimental kidney cancer drug trial halted early
NCT ID NCT04895748
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new drug called DFF332, which targets a protein (HIF2α) that helps some cancers grow. The study included 40 adults with advanced clear cell renal cell carcinoma or other cancers with specific gene changes. DFF332 was tested alone and in combination with other drugs, but the trial was terminated early, so we have limited information on its safety or effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DFF332 (a drug that targets HIF2α protein)
What this could lead to
If it worked, DFF332 might offer a new way to slow or stop certain kidney cancers by blocking a protein that helps tumors grow.
What could go wrong
This was a very early (phase 1) trial that was terminated, meaning it was stopped before completion. It involved only 40 people, so any benefits or risks are not well understood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope National Medical
Duarte, California, 91010, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloane Ketterin Cancer Ctr
New York, New York, 10065, United States
-
Novartis Investigative Site
Brno, 656 53, Czechia
-
Novartis Investigative Site
Villejuif, 94800, France
-
Novartis Investigative Site
Milan, MI, 20133, Italy
-
Novartis Investigative Site
Koto Ku, Tokyo, 1358550, Japan
-
Novartis Investigative Site
Singapore, 119228, Singapore
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas, 77030, United States
-
WA Uni School Of Med
St Louis, Missouri, 63110, United States